InvestSMART

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

Current share price for LDX : $0.110 0.005 (4.35%)+

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$104 Reinstatement to Quotation 16 Jul 2025 10:11AM $0.029 $0.110 risen by 279.31%
$104 Lumos Signs Pivotal US FebriDx Agreement 16 Jul 2025 10:11AM $0.029 $0.110 risen by 279.31%
$104 Suspension from Quotation 15 Jul 2025 9:09AM $0.029 $0.110 risen by 279.31%
$104 Trading Halt 11 Jul 2025 3:15PM $0.029 $0.110 risen by 279.31%
$104 Pause in Trading 11 Jul 2025 2:23PM $0.029 $0.110 risen by 279.31%
$104 Notification of cessation of securities - LDX 2 Jul 2025 12:09PM $0.028 $0.110 risen by 292.86%
$104 Lumos Receives Research & Development Tax Rebate 23 Jun 2025 9:01AM $0.029 $0.110 risen by 279.31%
$104 Lumos Reaches FebriDx CLIA Waiver Study Enrolment Milestone 18 Jun 2025 9:45AM $0.027 $0.110 risen by 307.41%
$104 FebriDx to Support Antimicrobial Stewardship in GP Trial 17 Jun 2025 9:02AM $0.028 $0.110 risen by 292.86%
$104 Change of Registered Office and Principal Place of Business 2 Jun 2025 9:08AM $0.028 $0.110 risen by 292.86%
$104 Lumos Reaches Recruitment Milestone in FebriDx Study 2 Jun 2025 9:05AM $0.028 $0.110 risen by 292.86%
$104 Lumos Secures Sixth US Medicare Reimbursement for FebriDx 27 May 2025 8:59AM $0.027 $0.110 risen by 307.41%
$104 Lumos Secures Fifth US Medicare Reimbursement for FebriDx 19 May 2025 9:59AM $0.027 $0.110 risen by 307.41%
$104 Lumos Advances FebriDx Sales with iMedical Purchase Order 14 May 2025 9:02AM $0.026 $0.110 risen by 323.08%
$104 Notification regarding unquoted securities - LDX 9 May 2025 10:32AM $0.027 $0.110 risen by 307.41%
$104 Q3 FY25 Investor Briefing 6 May 2025 8:45AM $0.028 $0.110 risen by 292.86%
$104 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2025 9:00AM $0.026 $0.110 risen by 323.08%
$104 Lumos Secures Further US Medicare Reimbursement for FebriDx 23 Apr 2025 10:46AM $0.025 $0.110 risen by 340%
$104 Lumos Secures Key US Reimbursement Milestones for FebriDx 17 Apr 2025 10:17AM $0.022 $0.110 risen by 400%
$104 Notification of cessation of securities - LDX 14 Apr 2025 12:02PM $0.022 $0.110 risen by 400%
$104 Investor Presentation 2 Apr 2025 11:26AM $0.025 $0.110 risen by 340%
$104 Investor Information Session Invitation 24 Mar 2025 1:53PM $0.023 $0.110 risen by 378.26%
$104 1H FY25 Results Investor Briefing 3 Mar 2025 10:58AM $0.027 $0.110 risen by 307.41%
$104 Hologic Development Agreement Expanded Scope of Works 3 Mar 2025 8:43AM $0.026 $0.110 risen by 323.08%
$104 Appendix 4D and Half Year Report 27 Feb 2025 8:30AM $0.030 $0.110 risen by 266.67%

126 - 150 of 544 results

Page 6 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.